Pablo Albiña Palmarola

Dr. Pablo Albiña Palmarola

Neuroradiologische Klinik, Klinikum Stuttgart, Stuttgart, Baden-Württemberg, Germany
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
MFM. Fujimoto
M. Fujimoto
ILI. Lylyk
I. Lylyk
BCBleise Daniel Carlos
Bleise Daniel Carlos
Pablo Albiña PalmarolaPablo Albiña Palmarola
Pablo Albiña Palmarola
JCJ. Chudyk
J. Chudyk
PLP. Lylyk
P. Lylyk
BACKGROUND AND PURPOSE: Treatment of wide-neck bifurcation aneurysms using endovascular therapy is still challenging even with the development of treatment devices. The purpose of this investigation was to assess the safety and efficacy of treatment with a Woven EndoBridge (WEB) device for wide-neck bifurcation aneurysms. MATERIALS AND METHODS: All patients treated with a WEB device at our institution between May 2009 and November 2016 were retrospectively evaluated. Clinical and imaging evaluation, aneurysm occlusion status, and modified Rankin scale score were analyzed 1 day after treatment and in the short- (<6 months), mid- (24 months) follow-up periods. RESULTS: Forty-one cases of wide-neck aneurysms were analyzed in this study. Overall, 78.8% of the aneurysms had complete occlusion in the last follow-up, and 19.5% required retreatment with additional endovascular devices. A good clinical outcome (modified Rankin scale: 0–2) was obtained in 95.1% of the patients, and the overall treatment-related morbidity and mortality rates were 2.4% and 0.0%, respectively. The mean follow-up time was 15.3 ± 13.5 months. CONCLUSIONS: The results obtained in this study suggest that treatment of wide-neck bifurcation aneurysms with a WEB device is feasible with an acceptable safety and efficacy rate.

15 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAMarcel Alfter
Marcel Alfter
Pablo Albiña PalmarolaPablo Albiña Palmarola
Pablo Albiña Palmarola
ACAlexandru Cimpoca
Alexandru Cimpoca
RPRoberto Diaz Peregrino
Roberto Diaz Peregrino
PJPaul Jans
Paul Jans
Hans HenkesHans Henkes
Hans Henkes
Purpose. The treatment of high-grade brain AVMs is challenging and has no guidelines available to date. This study was aimed at reporting the experience of two centers in treating these AVMs through a multi-stage approach consisting of preoperative embolization and microsurgical resection. Methods. A retrospective review was performed for 250 consecutive patients with a diagnosis of high-grade brain AVM (Spetzler–Martin grades III, IV, and V) treated in two centers in Germany between January 1989 and February 2023. The analyzed data included demographic, clinical, morphological, and neurological data. Results. A total of 150 cases (60%) were classified as Spetzler–Martin grade III, 82 cases (32.8%) were classified as grade IV, and 18 cases (7.2%) were classified as grade V. Eighty-seven cases (34.8%) presented with hemorrhage. The devascularization percentages achieved were 80% in 171 (68.4%) cases. The average number of sessions was 5.65 ± 5.50 and 1.11 ± 0.32 endovascular and surgical procedures, respectively, and did not significantly differ by rupture status. Death or dependency (mRS score ≥ 3) after the last follow-up was observed in 18.8% of patients and was significantly associated with age > 80 years and poor baseline neurological condition. The complete resection rate was 82.3% and was significantly associated with age > 80 years, large nidus, and deep venous drainage. Permanent disabling neurological deficit after at least 3 months of follow-up was diagnosed in 13.2% of patients and was significantly associated with age > 80 years and infratentorial locations. Conclusion. A multi-stage treatment for high-grade AVMs is feasible for selected cases but comes at a functional cost. The devascularization percentage was not associated with the investigated outcomes. Age > 80 years was associated with poor safety and effectiveness outcomes; consequently, this treatment should be offered only in exceptional circumstances.

9 December 2019 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
RMRafael Martinez-Perez
Rafael Martinez-Perez
HJHolger Joswig
Holger Joswig
ATAsterios Tsimpas
Asterios Tsimpas
TPTomas Poblete
Tomas Poblete
Pablo Albiña PalmarolaPablo Albiña Palmarola
Pablo Albiña Palmarola
JMJorge M. Mura
Jorge M. Mura

29 October 2020 in Interventional Neuroradiology
Verified
Journal Article
Closed access
PDF file
RVRene Viso
Rene Viso
ILIvan Lylyk
Ivan Lylyk
Pablo Albiña PalmarolaPablo Albiña Palmarola
Pablo Albiña Palmarola
JLJavier Lundquist
Javier Lundquist
ESEsteban Scrivano
Esteban Scrivano
PLPedro Lylyk
Pedro Lylyk
Introduction: Twig-like middle cerebral artery configuration (Tw-MCA) is a rare and commonly misdiagnosed vascular anomaly characterized by a plexiform arterial network that replaces the normal M1 segment. The prevalence and clinical relevance of this anomaly is not fully established. Material and methods: We sought to explore the prevalence of Tw-MCA in patients clinically referred to digital angiography in a single academic comprehensive endovascular center and evaluated the radiological and clinical findings among patients with hemorrhagic events. Results: From 2011 to 2020, a total of 10,234 patients underwent a cerebral angiography at our institution. During this period, 9 (0.088%) Tw-MCAs were identified. Out of these, 5 patients (62.5%) were admitted due to an intracranial hemorrhage. Two patients had a ruptured intracranial aneurysm on the anterior communicating artery, one with multiple brain aneurysms; two patients presented an intraparenchymal hematoma (IPH) due to the presence of a periventricular anastomosis and one patient an intraventricular hemorrhage with unclear origin. Conclusion: Tw-MCA is a very rare vascular anomaly associated with hemorrhagic events. Adequate identification of this anomaly is essential in order to avoid misdiagnosis as steno-occlusive disorders.

4 December 2019 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
RMRafael Martínez-Pérez
Rafael Martínez-Pérez
GSGiuliano Silveira-Bertazzo
Giuliano Silveira-Bertazzo
GRGustavo G. Rangel
Gustavo G. Rangel
Pablo Albiña PalmarolaPablo Albiña Palmarola
Pablo Albiña Palmarola
DHDouglas Hardesty
Douglas Hardesty
DPDaniel M. Prevedello
Daniel M. Prevedello

4 November 2025 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
KHKamran Hajiyev
Kamran Hajiyev
AKAli Khanafer
Ali Khanafer
PGPhilipp von Gottberg
Philipp von Gottberg
SMSebastian Johannes Müller
Sebastian Johannes Müller
Pablo Albiña PalmarolaPablo Albiña Palmarola
Pablo Albiña Palmarola
HHHans Henkes
Hans Henkes
Background: The optimal treatment approach for patients with severe atherosclerotic vertebral artery ostial stenosis (VAOS) is not yet supported by evidence from large-scale studies. Even with optimal medical treatment and effective risk factor management, substantial numbers of patients experience symptoms or recurrent strokes. Endovascular treatment is a potential solution, particularly when medicinal therapy alone is insufficient for symptom and stroke risk reduction. This study was aimed at assessing the safety and effectiveness of stent angioplasty in patients with VAOS. Methods: This single-centre retrospective analysis included 564 procedures in 525 patients (symptomatic n=265, without recent symptoms n=260; 72.2% male; median age: 70 years; stenosis >75% n=371) who underwent stenting for atherosclerotic VAOS between 2008 and 2022. Vertebrobasilar tandem lesions and dissections were excluded. Digital subtraction angiography was performed in all patients during the follow-up. Patients’ characteristics, periprocedural and postprocedural neurological events, and follow-up data were evaluated. Results: Stenting was successfully performed in all cases. The in-hospital stroke rate was 0.6% (disabling n=2; non-disabling n=1). No ipsilateral stroke or treatment-associated deaths occurred during a mean follow-up period of 56 months (min.–max., 9–183 months). In-stent restenosis >50% was found in 89 (15.8%) implanted stents, with the majority (70 out of 89) diagnosed within the first year, at a median time of 7 months. Conclusions: Stent angioplasty was demonstrated to be a safe and feasible option for patients with VAOS, with a low risk of periprocedural stroke and symptom recurrence, and favourable stent patency rates at mid-term and long-term follow-up.